Tumor News and Research

RSS

Sylvester Comprehensive Cancer Center opens new trial for neuroendocrine tumors

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Apr 2026

Targeted diet helps reprogram aggressive neuroblastoma in mice

Researchers highlighted how an arginine- and proline-restricted diet combined with eflornithine reprogrammed MYCN-driven neuroblastoma in mice, pushing tumor cells out of the cell cycle and toward differentiation. The commentary argues that this metabolism-to-translation link could open a new path for testing targeted dietary strategies alongside cancer drugs in future clinical studies.

9 Apr 2026

New 3D organoid model advances pediatric glioma research and treatment

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children.

9 Apr 2026

AI-powered chemistry accelerates discovery of selective cancer inhibitors

Recently, the Insilico team's research entitled "An Internal Sulfur-Lone Pair Interaction Enabled the Discovery of Potential and Sub-Family Selective PKMYT1 Inhibitors" was invited for publication as a cover Feature in ChemMedChem.

9 Apr 2026

Precision medicine tools offer hope for patients with rare blood cancers

Personalized approaches have dramatically improved outcomes for many patients with non-Hodgkin B-cell lymphomas—blood cancers that arise in immune cells called B cells—yet the same is not true for patients with more rare lymphoma types that originate in immune cells called T cells.

9 Apr 2026

Study explains why current BET inhibitors fail in cancer treatment

For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations.

9 Apr 2026

Microplastics found in human bile may be associated with gallstones

Findings show microplastics in bile may trigger cellular senescence, suggesting a link to gallstone disease and highlighting the need for further research.

9 Apr 2026

Preconditioned skin cells enable faster and more effective wound healing

It is well known that students who prepare in advance perform better on exams. Now, it appears that the skin can do the same.

8 Apr 2026

Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor vital for maintaining physiological homeostasis, and inhibition of NR3C1 could increase the sensitivity of cancer cells to standard chemotherapy, particularly in ovarian cancer.

8 Apr 2026

Clusterin inhibition offers new hope for treating cervical gastric-type adenocarcinoma

Gastric-type adenocarcinoma (GAS) is one of the most aggressive non-human papillomavirus (HPV)-associated cervical adenocarcinomas and remains especially difficult to diagnose and treat.

8 Apr 2026

Future CAR therapy expands beyond T cells to treat diverse diseases

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies.

8 Apr 2026

High affinity for immune receptors predicts antibody drug associated anaphylaxis risk

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory molecules.

8 Apr 2026

CIPHER-seq technology reveals how immune cells communicate during treatment

A new single-cell technology is giving scientists their clearest view yet of immune cell behavior-capturing not just genetic intent but real-time activity.

8 Apr 2026

Noninvasive urine test improves prediction of bladder cancer treatment outcomes

Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called non-muscle invasive bladder cancer (NMIBC), in which the tumors are confined to the inner layers of the bladder.

7 Apr 2026

New blood test spots four cancers and other diseases by stripping away healthy DNA noise

MethylScan is a new low-cost cell-free DNA methylome test that removes much of the healthy blood DNA background, helping rare disease signals stand out more clearly. In more than 1,000 people, it showed strong performance for detecting four cancers, classifying liver diseases, and identifying organ-specific damage.

7 Apr 2026

Pol theta enzyme identified as key driver of cancer resilience

A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential than researchers realized.

7 Apr 2026

Lactate modification fuels drug resistance and immune escape in cancer

Published in Current Molecular Pharmacology, a comprehensive review led by Yong Xu and colleagues from Shanghai Pulmonary Hospital explores the emerging role of lactylation, a post-translational modification driven by lactate, in lung cancer progression and drug resistance.

7 Apr 2026

Blocking nitric oxide suppresses tumor growth in aggressive pediatric neuroblastoma

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born harboring a malignancy that may not declare itself for months.

7 Apr 2026

New blood biomarker improves cancer risk detection in people with Lynch Syndrome

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch Syndrome (LS) who are more susceptible to developing cancer based on early immune detection signatures, allowing clinicians to stratify patients based on their personal risk level.

6 Apr 2026

New technique can simultaneously treat lung cancer and muscle-wasting condition

Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it.

6 Apr 2026